Banco Bilbao Vizcaya Argentaria S.A. Buys 10,425 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 98,221 shares of the pharmaceutical company's stock after purchasing an additional 10,425 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Vertex Pharmaceuticals were worth $47,664,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $31,000. Mpwm Advisory Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $40,000. Minot DeBlois Advisors LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $44,000. Finally, SJS Investment Consulting Inc. increased its stake in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after buying an additional 30 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on VRTX shares. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research note on Tuesday, August 5th. Guggenheim reduced their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Wolfe Research downgraded Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a report on Wednesday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Vertex Pharmaceuticals Price Performance

VRTX traded up $3.10 on Thursday, hitting $397.46. The company had a trading volume of 1,851,693 shares, compared to its average volume of 2,487,458. The stock has a market cap of $101.90 billion, a price-to-earnings ratio of 28.41 and a beta of 0.44. The company's fifty day moving average price is $440.20 and its 200 day moving average price is $462.13. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter last year, the firm posted ($12.83) earnings per share. The company's quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.